The dose of STZ is designed to produce a partial impairment of insulin secretion, and the resultant phenotype is similar to advanced type 2 diabetes (T2D) where beta cells are functionally exhausted and fail to secrete insulin at normal levels23. This evidence concerns the gene INS and type 2 diabetes mellitus.